BLAME/SLAMF8 Antibody

Western Blot: BLAME/SLAMF8 Antibody [NBP2-26110] -

(a) The overexpression of SLAMF8 in AD cell models increased the levels of TLR4/NF-kappa B signaling-related markers (TLR4, p-I kappaB alpha/I kappaB alpha ratio) and the phospho-p65/p65 ratio, as confirmed by Western blot. Quantification of the Western blot results was performed and normalized against beta-actin (n = 3) (a1). (b) Conversely, knockdown of SLAMF8 produced the opposite effect and the data were quantified and normalized to beta-actin (n = 3). (b1) The TLR4/NF-kappa B signaling inhibitor TAK-242 suppressed TLR4 expression (c,c1) and mitigated the increase in ROS (d,e) and neuroinflammation (f) caused by SLAMF8 overexpression in AD cell models. Data are presented as mean +/- standard deviation. One-way ANOVA with Tukey’s post hoc test was used for multiple group comparisons, and a paired t-test was used for comparisons between two groups. “*" indicates p ≤ 0.05, and “**" indicates p ≤ 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40394132), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: BLAME/SLAMF8 Antibody [NBP2-26110] -

(a,b) Knockdown of NINJ2 significantly abolished SLAMF8-induced oxidative stress, reduced ROS levels (DCF and MitoSOX Red), and decreased NOX2 and NOX4 expression in A beta1-42-treated SH-SY5Y cells. (c) Similarly, knockdown of NINJ2 significantly reduced the SLAMF8-treated neuroinflammation in LPS-treated HMC3 cells. (d) In SLAMF8-stably overexpressing AD cell models, transient knockdown of NINJ2 with siNINJ2 for 48 h significantly abolished SLAMF8-induced p65 phosphorylation in the TLR4/NF-kappa B signaling pathway. Data are presented as mean +/- standard deviation. One-way ANOVA with Tukey’s post hoc test was used for multiple group comparisons, and a paired t-test was used for comparisons between two groups. “*" indicates p ≤ 0.05, and “**" indicates p ≤ 0.01.. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40394132), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: BLAME/SLAMF8 Antibody [NBP2-26110] -

(a) The overexpression of SLAMF8 in AD cell models increased the levels of TLR4/NF-kappa B signaling-related markers (TLR4, p-I kappaB alpha/I kappaB alpha ratio) and the phospho-p65/p65 ratio, as confirmed by Western blot. Quantification of the Western blot results was performed and normalized against beta-actin (n = 3) (a1). (b) Conversely, knockdown of SLAMF8 produced the opposite effect and the data were quantified and normalized to beta-actin (n = 3). (b1) The TLR4/NF-kappa B signaling inhibitor TAK-242 suppressed TLR4 expression (c,c1) and mitigated the increase in ROS (d,e) and neuroinflammation (f) caused by SLAMF8 overexpression in AD cell models. Data are presented as mean +/- standard deviation. One-way ANOVA with Tukey’s post hoc test was used for multiple group comparisons, and a paired t-test was used for comparisons between two groups. “*" indicates p ≤ 0.05, and “**" indicates p ≤ 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40394132), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: BLAME/SLAMF8 Antibody [NBP2-26110] -

(a) The overexpression of SLAMF8 in AD cell models increased the levels of TLR4/NF-kappa B signaling-related markers (TLR4, p-I kappaB alpha/I kappaB alpha ratio) and the phospho-p65/p65 ratio, as confirmed by Western blot. Quantification of the Western blot results was performed and normalized against beta-actin (n = 3) (a1). (b) Conversely, knockdown of SLAMF8 produced the opposite effect and the data were quantified and normalized to beta-actin (n = 3). (b1) The TLR4/NF-kappa B signaling inhibitor TAK-242 suppressed TLR4 expression (c,c1) and mitigated the increase in ROS (d,e) and neuroinflammation (f) caused by SLAMF8 overexpression in AD cell models. Data are presented as mean +/- standard deviation. One-way ANOVA with Tukey’s post hoc test was used for multiple group comparisons, and a paired t-test was used for comparisons between two groups. “*" indicates p ≤ 0.05, and “**" indicates p ≤ 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40394132), licensed under a CC-BY license. Not internally tested by Novus Biologicals.